Cisplatin upregulates MSH2 expression by reducing miR-21 to inhibit A549 cell growth

Biomedicine and Pharmacotherapy

Volumn 67, Issue 2, 2013, Pages 97-102

  Zhang, Yan Xia ^a   Yue, Zhen ^a   Wang, Ping Yu ^a   Li, You Jie ^a   Xin, Jia Xuan ^a   Pang, Min ^a   Zheng, Qing Yin ^b   Xie, Shu Yang ^a  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Cisplatin; Gene expression; Lung cancer; MicroRNA; MSH2

Indexed keywords

CISPLATIN; GREEN FLUORESCENT PROTEIN; MICRORNA 21; PROTEIN MSH2;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; XENOGRAFT;

3' UNTRANSLATED REGIONS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MUTS HOMOLOG 2 PROTEIN; UP-REGULATION;

EID: 84875375142     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.11.008     Document Type: Article

References (39)

1. Chen J., Ye L., Xie F., Yang Y., Zhang L., Jiang W.G. Expression of bone morphogenetic protein 7 in lung cancer and its biological impact on lung cancer cells. Anticancer Res 2010, 30:1113-1120.
2. Zhao P., Dai M., Chen W., Li N. Cancer trends in China. Jpn J Clin Oncol 2010, 40:281-285.
3. Siegel R., Naishadham D., Jemal A. Cancer Statistics. CA Cancer J Clin 2012, 62:10-29.
4. Herbst R.S., Heymach J.V., Lippman S.M. Lung Cancer. N Engl J Med 2008, 359:1367-1380.
5. Selvaggi G., Scagliotti G.V. Histologic subtype in NSCLC: does it matter?. Oncology (Williston Park) 2009, 23:1133-1140.
6. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
7. Wibom C., Sjöström S., Henriksson R., Brännström T., Broholm H., Rydén P., et al. DNA repair gene variants are associated with glioblastoma survival. Acta Oncol 2012, 51:325-332.
8. Spitz M.R., Wei Q., Dong Q., Amos C.I., Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003, 12:689-698.
9. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: Revising the mutator hypothesis. Cancer Res 2001, 61:7369-7374.
10. Fishel R., Ewel A., Lescoe M.K. Purified human MSH2 protein binds to DNA containing mismatched nucleotides. Cancer Res 1994, 54:5539-5542.
11. Lynch H.T., de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003, 348:919-932.
12. Jun S.H., Kim T.G., Ban C. DNA mismatch repair system classical and fresh roles. FEBS J 2006, 273:1609-1619.
13. Meyers M., Wagner M.W., Mazurek A., Schmutte C., Fishel R., Boothman D.A. DNA mismatch repair-dependent response to fluoropyrimidine-generated damage. J Biol Chem 2005, 280:5516-5526.
14. Gong J.G., Costanzo A., Yang H.Q., Melino G., Kaelin W.G., Levrero, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 1999, 399:806-809.
15. Zhang H., Richards B., Wilson T., Lloyd M., Cranston A., Thorburn A., et al. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 1999, 59:3021-3027.
16. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
17. Bhattacharyya S.N., Habermacher R., Martine U., Closs E.I., Filipowicz W. Stress induced reversal of microRNA repression and mRNA P-body localization in human cells. Cold Spring Harb Symp Quant Biol 2006, 71:513-521.
18. Ambros V. MicroRNA pathways in flies mini review and worms: growth, death, fat, stress and timing. Cell 2003, 113:673-676.
19. Wang P.Y., Li Y.J., Zhang S., Li Z.L., Yue Z., Xie S.Y., et al. Regulating A549 cells growth by ASO inhibiting miRNAexpression. Mol Cell Biochem 2010, 339:163-171.
20. Li Y.J., Zhang Y.X., Wang P.Y., Chi Y.L., Zhang C., Xie S.Y., et al. Regression of A549 lung cancer tumors by anti-miR-150 vector. Oncol Rep 2012, 27:129-134.
21. Si M.L., Zhu S., Wu H., Lu Z., Wu F., Mo Y.Y. miR-21-mediated tumor growth. Oncogene 2007, 26:2799-2803.
22. Buscaglia L.E., Li Y. Apoptosis and the target genes of microRNA-21. Chin J Cancer 2011, 30:371-380.
23. Fan T., Li R., Todd N.W., Qiu Q., Fang H.B., Wang H., et al. Upregulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007, 67:7901-7906.
24. Zhang S., Zhang C., Li Y., Wang P., Yue Z., Xie S. miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomed Pharmacother 2011, 65:436-442.
25. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005, 33:1290-1297.
26. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
27. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103:2257-2261.
28. Schetter A.J., Leung S.Y., Sohn J.J., Zanetti K.A., Bowman E.D., Yanaihara N., et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008, 299:425-436.
29. Zaman M.S., Shahryari V., Deng G., Thamminana S., Saini S., Majid S., et al. Upregulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 2012, 7:e31060.
30. Kusenda B., Mraz M., Mayer J., Pospisilova S. MicroRNA biogenesis, functionality and cancer relevance. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2006, 150:205-215.
31. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
32. Cao Z., Yoon J.H., Nam S.W., Lee J.Y., Park W.S. PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J Cancer Res Clin Oncol 2012, 138:611-619.
33. Zhu S., Si M.L., Wu H., Mo Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007, 282:14328-14336.
34. Acharya S., Wilson T., Gradia S., Kane M.F., Guerrette S., Marsischky G.T., et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci USA 1996, 93:13629-13634.
35. Bartley A.N., Luthra R., Saraiya D.S., Urbauer D.L., Broaddus R.R. Identification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue based mismatch repair testing. Cancer Prev Res (Phila) 2012, 5:320-327.
36. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res 2001, 61:7369-7374.
37. Lin D.P., Wang Y., Scherer S.J., Clark A.B., Yang K., Avdievich E., et al. An MSH2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res 2004, 64:517-522.
38. Dedoussis G.V., Mouzaki A., Theodoropoulou M., Menounos P., Kyrtsonis M.C., Karameris A., et al. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line. Exp Cell Res 1999, 249:269-278.
39. Xie S.Y., Li Y.J., Wang P.Y., Jiao F., Zhang S., Zhang W.J. miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells. Oncol Rep 2010, 23:1693-1700.